AUPH
Price
$16.21Alerts
Change
-$0.09 (-0.55%)
Updated
Nov 11 closing price
Capitalization
2.19B
112 days until earnings call
Intraday BUY SELL Signals
BCDA
Price
$0.92Alerts
Change
-$0.01 (-1.08%)
Updated
Nov 11 closing price
Capitalization
12.87M
Earnings call today
Intraday BUY SELL Signals
Interact to see
Advertisement

AUPH vs BCDA

AUPH vs BCDA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
AUPH vs. BCDA commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AUPH is a Hold and BCDA is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for AUPH with price predictions
Nov 11, 2026

AUPH in upward trend: 10-day moving average crossed above 50-day moving average on October 15, 2026

The 10-day moving average for AUPH crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a +2.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where AUPH advanced for three days, in 215 of 267 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

AUPH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 137 of 165 cases where AUPH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.

Bearish Trend Analysis

The 10-day RSI Indicator for AUPH moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 23 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.

The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AUPH as a result. In 74 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.

The Moving Average Convergence Divergence Histogram (MACD) for AUPH turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 45 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.

AUPH moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AUPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 18 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. AUPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.562) is normal, around the industry mean (3.498). P/E Ratio (6.975) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (7.429) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AUPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for BCDA with price predictions
Nov 11, 2026

BCDA's RSI Oscillator ascends from oversold territory

The RSI Indicator for BCDA moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In 27 of the 31 cases the stock moved higher. This puts the odds of a move higher at 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 64 cases where BCDA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.

The Moving Average Convergence Divergence (MACD) for BCDA just turned positive on November 10, 2026. Looking at past instances where BCDA's MACD turned positive, the stock continued to rise in 38 of 47 cases over the following month. The odds of a continued upward trend are 81%.

Following a +9.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where BCDA advanced for three days, in 183 of 236 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

BCDA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BCDA as a result. In 95 of 103 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

BCDA moved below its 50-day moving average on October 09, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for BCDA crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 17 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 89%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCDA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

The Aroon Indicator for BCDA entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. BCDA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.766) is normal, around the industry mean (3.498). P/E Ratio (-1.441) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.090) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2000.000) is also within normal values, averaging (440.869).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCDA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
AUPH vs BCDA: Fundamental Ratings
AUPH
BCDA
OUTLOOK RATING
1..100
2255
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
87
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
18100
PRICE GROWTH RATING
1..100
5061
P/E GROWTH RATING
1..100
9636
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AUPH's Valuation (79) in the Biotechnology industry is in the same range as BCDA (87) in the null industry. This means that AUPH’s stock grew similarly to BCDA’s over the last 12 months.

AUPH's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as BCDA (100) in the null industry. This means that AUPH’s stock grew similarly to BCDA’s over the last 12 months.

AUPH's SMR Rating (18) in the Biotechnology industry is significantly better than the same rating for BCDA (100) in the null industry. This means that AUPH’s stock grew significantly faster than BCDA’s over the last 12 months.

AUPH's Price Growth Rating (50) in the Biotechnology industry is in the same range as BCDA (61) in the null industry. This means that AUPH’s stock grew similarly to BCDA’s over the last 12 months.

BCDA's P/E Growth Rating (36) in the null industry is somewhat better than the same rating for AUPH (96) in the Biotechnology industry. This means that BCDA’s stock grew somewhat faster than AUPH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AUPHBCDA
RSI
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
87%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
84%
Momentum
ODDS (%)
Bearish Trend 1 day ago
73%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
75%
Bullish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 2 days ago
78%
Declines
ODDS (%)
Bearish Trend 1 day ago
73%
Bearish Trend 6 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
80%
Aroon
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
85%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (AUPH: $16.30 vs. BCDA: $0.92)
Brand notoriety: AUPH and BCDA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AUPH: 93% vs. BCDA: 34%
Market capitalization -- AUPH: $2.19B vs. BCDA: $12.87M
AUPH [@Biotechnology] is valued at $2.19B. BCDA’s [@Biotechnology] market capitalization is $12.87M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AUPH’s FA Score shows that 1 FA rating(s) are green while BCDA’s FA Score has 0 green FA rating(s).

  • AUPH’s FA Score: 1 green, 4 red.
  • BCDA’s FA Score: 0 green, 5 red.
According to our system of comparison, AUPH is a better buy in the long-term than BCDA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AUPH’s TA Score shows that 5 TA indicator(s) are bullish while BCDA’s TA Score has 6 bullish TA indicator(s).

  • AUPH’s TA Score: 5 bullish, 5 bearish.
  • BCDA’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, BCDA is a better buy in the short-term than AUPH.

Price Growth

AUPH (@Biotechnology) experienced а -1.57% price change this week, while BCDA (@Biotechnology) price change was +0.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

AUPH is expected to report earnings on Mar 04, 2027.

BCDA is expected to report earnings on Mar 30, 2027.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

AUPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, AUPH has been loosely correlated with JSPR. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if AUPH jumps, then JSPR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AUPH
1D Price
Change %
AUPH100%
-0.55%
JSPR - AUPH
44%
Loosely correlated
+0.07%
VCYT - AUPH
39%
Loosely correlated
+4.36%
JBIO - AUPH
38%
Loosely correlated
+0.85%
DYN - AUPH
38%
Loosely correlated
+0.39%
NAMS - AUPH
38%
Loosely correlated
+8.03%
More

BCDA and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCDA has been loosely correlated with XRTX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if BCDA jumps, then XRTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCDA
1D Price
Change %
BCDA100%
-0.91%
XRTX - BCDA
43%
Loosely correlated
+4.72%
MDGL - BCDA
29%
Poorly correlated
+0.10%
INO - BCDA
28%
Poorly correlated
+1.72%
KOD - BCDA
28%
Poorly correlated
+1.18%
AUPH - BCDA
27%
Poorly correlated
-0.55%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
KDEF31.061.47
+4.97%
Plus Korea Defense Industry Index ETF
UOCT42.380.32
+0.76%
Innovator U.S. Equity Ultra Buffer ETF - October (UOCT)
TLTX20.710.10
+0.50%
Global X Treasury Bond Enhanced Income ETF (TLTX)
XTAI17.26N/A
N/A
Corgi Taiwan 2x Daily ETF (XTAI)
FPF15.79-0.05
-0.32%
FIRST TRUST INTERMEDIATE DURATION PREFERRED & Income FUND